Currently, there are 696.83M common shares owned by the public and among those 75.96M shares have been available to trade.
The company’s stock has a 5-day price change of 2.29% and -27.96% over the past three months. IBRX shares are trading -46.61% year to date (YTD), with the 12-month market performance down to -48.56% lower. It has a 12-month low price of $2.50 and touched a high of $10.53 over the same period. IBRX has an average intraday trading volume of 6.33 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -22.97%, -38.61%, and -48.01% respectively.
Institutional ownership of ImmunityBio Inc (NASDAQ: IBRX) shares accounts for 9.44% of the company’s 696.83M shares outstanding.
It has a market capitalization of $2.02B and a beta (3y monthly) value of 0.69. The earnings-per-share (ttm) stands at -$0.89. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.47% over the week and 7.58% over the month.
Earnings per share for the fiscal year are expected to increase by 27.54%, and 19.20% over the next financial year. EPS should shrink at an annualized rate of -1.70% over the next five years, compared to 1.17% over the past 5-year period.
Looking at the support for the IBRX, a number of firms have released research notes about the stock. Piper Sandler stated their Neutral rating for the stock in a research note on May 12, 2023, with the firm’s price target at $10-$4. Jefferies coverage for the ImmunityBio Inc (IBRX) stock in a research note released on August 03, 2022 offered a Buy rating with a price target of $8.
